Journal
IMMUNITY
Volume 54, Issue 9, Pages 2133-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2021.08.001
Keywords
-
Categories
Funding
- NIH [AI105343, AI108545, AI155577, AI149680, AI152236, AI082630, HL143613, T32 AR076951-01, T32 CA009140, T32 AI055400, U19AI082630, 75N9301900065]
- Allen Institute for Immunology
- Cancer Research Institute-Mark Foundation Fellowship
- Chen Family Research Fund
- Parker Institute for Cancer Immunotherapy
- Penn Center for Research on Coronavirus and Other Emerging Pathogens
- University of Pennsylvania Perelman School of Medicine COVID Fund
- University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund
Ask authors/readers for more resources
The study found that after SARS-CoV-2 mRNA vaccination, CD4(+) T cell responses in naïve individuals were fast, while CD8(+) T cell responses developed gradually. Th1 and Tfh cell responses after the first dose were correlated with post-boost CD8(+) T cells and neutralizing antibodies.
SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific T cell analyses on healthy SARS-CoV-2-naive and recovered individuals prior to and following mRNA prime and boost vaccination. Vaccination induced rapid antigen-specific CD4(+) T cell responses in naive subjects after the first dose, whereas CD8(+) T cell responses developed gradually and were variable in magnitude. Vaccine-induced Th1 and Tfh cell responses following the first dose correlated with post-boost CD8(+) T cells and neutralizing antibodies, respectively. Integrated analysis revealed coordinated immune responses with distinct trajectories in SARS-CoV-2-naive and recovered individuals. Last, whereas booster vaccination improved T cell responses in SARS-CoV-2- naive subjects, the second dose had little effect in SARS-CoV-2-recovered individuals. These findings highlight the role of rapidly primed CD4(+) T cells in coordinating responses to the second vaccine dose in SARS-CoV-2-naive individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available